Arbutus (ABUS) stock sinks as the European Patent Office revokes a patent that was subject to a legal dispute between the ...
Investing.com -- Arbutus Biopharma Corporation stock fell 7% on Friday following news that the Board of Appeal of the ...
Shares of Arbutus Biopharma slid after the company said the European Patent Office had revoked one of its patents. The stock slipped 12%, to $4.15, midday Friday, but has gained 29% in the past year.
Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.
Zacks Investment Research on MSN
Arbutus (ABUS) upgraded to buy: Here's what you should know
Arbutus Biopharma (ABUS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
While Arbutus Biopharma is busy scrapping with Moderna and Pfizer over COVID-19 vaccine patents, Moderna has chalked up a win in a separate case. Back in 2018, Moderna challenged one of Arbutus’ lipid ...
Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for ...
WARMINSTER, Pa., March 26, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced positive preliminary results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback